Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Phase 1/2 Recruiting
768 enrolled
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
392 enrolled
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Phase 2 Recruiting
160 enrolled
I-SPY
Phase 2 Recruiting
5,000 enrolled
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Phase 2 Recruiting
30 enrolled
EmpowHER 208
Phase 2 Recruiting
125 enrolled
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
Phase 2 Recruiting
53 enrolled
A Study of Surgery and Radiotherapy in People With Breast Cancer
Phase 2 Recruiting
162 enrolled
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
Phase 3 Recruiting
540 enrolled
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
Phase 4 Recruiting
10 enrolled
Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study
Phase 2 Recruiting
30 enrolled
H3RAKLES
Phase 2 Recruiting
20 enrolled
MK-1022-009
Phase 1/2 Recruiting
81 enrolled
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
Phase 2 Recruiting
50 enrolled
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Phase 3 Recruiting
1,524 enrolled
ASPEN-09
Phase 1/2 Recruiting
80 enrolled
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
Phase 3 Recruiting
740 enrolled
TAYLOR
Phase 2 Recruiting
200 enrolled
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
Phase 2 Recruiting
30 enrolled
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
Phase 1 Recruiting
28 enrolled
RAGE
Phase 1/2 Recruiting
48 enrolled
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Phase 1 Recruiting
113 enrolled
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
Phase 2 Recruiting
25 enrolled
Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
Phase 3 Recruiting
300 enrolled
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Phase 3 Recruiting
544 enrolled
PIKture-01
Phase 1 Recruiting
200 enrolled
ARIADNE
Phase 2 Recruiting
370 enrolled
A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)
Phase 3 Recruiting
2,306 enrolled
BRE-10
Phase 2 Recruiting
28 enrolled
Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
Phase 3 Recruiting
812 enrolled
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
Phase 2 Recruiting
72 enrolled
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
Phase 2 Recruiting
180 enrolled
Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
Phase 3 Recruiting
880 enrolled
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Phase 1/2 Recruiting
18 enrolled
Neo-Healer
Phase 3 Recruiting
520 enrolled
Pre Operative Trastuzumab in Operable Breast Cancer
Phase 3 Recruiting
1,100 enrolled
SCHOLAR-2
Phase 2 Recruiting
130 enrolled
TUC-TOC
Phase 2 Recruiting
66 enrolled
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
Phase 2 Recruiting
240 enrolled
Pyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer
Phase NA Recruiting
30 enrolled
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Phase 1/2 Recruiting
1,000 enrolled
RESPONSE
Phase 2 Recruiting
185 enrolled
Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
Phase 2 Recruiting
33 enrolled
Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer
Phase 2 Recruiting
65 enrolled
IRIS
Phase 2 Recruiting
356 enrolled
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
Phase 4 Recruiting
100 enrolled
Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
Phase 3 Recruiting
312 enrolled
The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study
Phase 2 Recruiting
102 enrolled
Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
Phase 3 Recruiting
372 enrolled
TRAIN-4
Phase 1 Recruiting
30 enrolled